Otamixaban: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
| verifiedrevid = 462266309 | | verifiedrevid = 462266309 | ||
| IUPAC_name = Methyl (2''R'',3''R'')-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate | | IUPAC_name = Methyl (2''R'',3''R'')-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate | ||
| image = Otamixaban. | | image = Otamixaban.png | ||
| image2 = Otamixaban 3D.png | | image2 = Otamixaban 3D.png | ||
| Line 51: | Line 51: | ||
| StdInChIKey = PFGVNLZDWRZPJW-OPAMFIHVSA-N | | StdInChIKey = PFGVNLZDWRZPJW-OPAMFIHVSA-N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Otamixaban''' ([[International Nonproprietary Name|INN]]) is an experimental injectable [[anticoagulant]] [[direct factor Xa inhibitor]],<ref name="pmid17979700">{{cite journal |author=Guertin KR, Choi YM |title=The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development |journal=Curr. Med. Chem. |volume=14 |issue=23 |pages=2471–81 |year=2007 |pmid=17979700 |doi= 10.2174/092986707782023659|url=http://openurl.ingenta.com/content/nlm?genre=article&issn=0929-8673&volume=14&issue=23&spage=2471&aulast=Guertin}}</ref> that was investigated for the treatment for [[acute coronary syndrome]]. In 2013, [[Sanofi]] announced that it had ended [[drug development|development]] of the drug candidate after poor performance in a [[Phase III clinical trial]].<ref>{{cite journal | journal = Chemical & Engineering News | publisher = American Chemical Society | date = June 10, 2013 | volume = 91 | number = 23 | page = 17 | title = AstraZeneca, Sanofi Cut Programs | quote = Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.}}</ref><ref>{{cite web|title=Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs|url=http://www.rttnews.com/2129222/sanofi-s-investigational-iniparib-otamixaban-fail-to-meet-goals-ends-programs.aspx|publisher=RTT news|accessdate=11 April 2014}}</ref> | '''Otamixaban''' ([[International Nonproprietary Name|INN]]) is an experimental injectable [[anticoagulant]] [[direct factor Xa inhibitor]],<ref name="pmid17979700">{{cite journal |author=Guertin KR, Choi YM |title=The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development |journal=Curr. Med. Chem. |volume=14 |issue=23 |pages=2471–81 |year=2007 |pmid=17979700 |doi= 10.2174/092986707782023659|url=http://openurl.ingenta.com/content/nlm?genre=article&issn=0929-8673&volume=14&issue=23&spage=2471&aulast=Guertin}}</ref> that was investigated for the treatment for [[acute coronary syndrome]]. In 2013, [[Sanofi]] announced that it had ended [[drug development|development]] of the drug candidate after poor performance in a [[Phase III clinical trial]].<ref>{{cite journal | journal = Chemical & Engineering News | publisher = American Chemical Society | date = June 10, 2013 | volume = 91 | number = 23 | page = 17 | title = AstraZeneca, Sanofi Cut Programs | quote = Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.}}</ref><ref>{{cite web|title=Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs|url=http://www.rttnews.com/2129222/sanofi-s-investigational-iniparib-otamixaban-fail-to-meet-goals-ends-programs.aspx|publisher=RTT news|accessdate=11 April 2014}}</ref> | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{Antithrombotics}} | {{Antithrombotics}} | ||
[[Category:Drug]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Anticoagulants]] | [[Category:Anticoagulants]] | ||
Latest revision as of 19:46, 27 July 2014
{{Drugbox | Verifiedfields = changed | verifiedrevid = 462266309 | IUPAC_name = Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate | image = Otamixaban.png | image2 = Otamixaban 3D.png
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number_Ref = 
| CAS_number = 193153-04-7
| ATC_prefix = none
| ATC_suffix =
| PubChem = 5496659
| DrugBank_Ref = 
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID = 4593439
| UNII_Ref =
| UNII = S173RED00L
| ChEMBL_Ref =
| ChEMBL = 46618
| C=25 | H=26 | N=4 | O=4
| molecular_weight = 446.498 g/mol
| smiles = O=C(OC)[C@H](Cc1cc(C(=[N@H])N)ccc1)[C@H](NC(=O)c3ccc(c2cc[n+]([O-])cc2)cc3)C
| InChI = 1/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
| InChIKey = PFGVNLZDWRZPJW-OPAMFIHVBD
| StdInChI_Ref =
| StdInChI = 1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
| StdInChIKey_Ref =
| StdInChIKey = PFGVNLZDWRZPJW-OPAMFIHVSA-N
}}
|
WikiDoc Resources for Otamixaban |
|
Articles |
|---|
|
Most recent articles on Otamixaban |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Otamixaban at Clinical Trials.gov Clinical Trials on Otamixaban at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Otamixaban
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Otamixaban Discussion groups on Otamixaban Patient Handouts on Otamixaban Directions to Hospitals Treating Otamixaban Risk calculators and risk factors for Otamixaban
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Otamixaban |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor,[1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.[2][3]
References
- ↑ Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. doi:10.2174/092986707782023659. PMID 17979700.
- ↑ "AstraZeneca, Sanofi Cut Programs". Chemical & Engineering News. American Chemical Society. 91 (23): 17. June 10, 2013.
Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.
- ↑ "Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs". RTT news. Retrieved 11 April 2014.